These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39023617)

  • 21. UGT genotyping in belinostat dosing.
    Goey AK; Figg WD
    Pharmacol Res; 2016 Mar; 105():22-7. PubMed ID: 26773202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.
    Sawas A; Ma H; Shustov A; Hsu P; Bhat G; Acosta M; Horwitz S; O'Connor OA
    Leuk Lymphoma; 2020 Aug; 61(8):2003-2007. PubMed ID: 32336176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.
    Puvvada SD; Li H; Rimsza LM; Bernstein SH; Fisher RI; LeBlanc M; Schmelz M; Glinsmann-Gibson B; Miller TP; Maddox AM; Friedberg JW; Smith SM; Persky DO
    Leuk Lymphoma; 2016 Oct; 57(10):2359-69. PubMed ID: 26758422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beleodaq approved for rare lymphomas.
    Cancer Discov; 2014 Sep; 4(9):978. PubMed ID: 25185167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL).
    Lu G; Jin S; Lin S; Gong Y; Zhang L; Yang J; Mou W; Du J
    Clin Epigenetics; 2023 Aug; 15(1):124. PubMed ID: 37533111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.
    Broccoli A; Argnani L; Zinzani PL
    Cancer Treat Rev; 2017 Nov; 60():120-129. PubMed ID: 28946015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Belinostat: clinical applications in solid tumors and lymphoma.
    Molife LR; de Bono JS
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1723-32. PubMed ID: 22046971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.
    Kirschbaum MH; Foon KA; Frankel P; Ruel C; Pulone B; Tuscano JM; Newman EM
    Leuk Lymphoma; 2014 Oct; 55(10):2301-4. PubMed ID: 24369094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Belinostat (Beleodaq) for peripheral T-Cell lymphoma.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):e66-7. PubMed ID: 25988963
    [No Abstract]   [Full Text] [Related]  

  • 30. Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRI.
    Gurbani SS; Yoon Y; Weinberg BD; Salgado E; Press RH; Cordova JS; Ramesh KK; Liang Z; Velazquez Vega J; Voloschin A; Olson JJ; Schreibmann E; Shim H; Shu HG
    Tomography; 2019 Mar; 5(1):53-60. PubMed ID: 30854442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective phase 2 study of combination epigenetic therapy against relapsed/refractory peripheral T cell lymphoma.
    Ding K; Liu H; Yang H; Zhu H; Ma J; Peng H; Huang H; Shi W; Cao L; Wu W; Zhao X; Shi X; Li J; Zhang X; Fan L
    Med; 2024 Nov; 5(11):1393-1401.e2. PubMed ID: 39084226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma.
    Wang J; Fang Y; Ma S; Su N; Zhang Y; Huang H; Li Z; Huang H; Tian X; Cai J; Xia Y; Liu P; Cai Q
    Leuk Res; 2021 Dec; 111():106705. PubMed ID: 34534908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
    Mackay HJ; Hirte H; Colgan T; Covens A; MacAlpine K; Grenci P; Wang L; Mason J; Pham PA; Tsao MS; Pan J; Zwiebel J; Oza AM
    Eur J Cancer; 2010 Jun; 46(9):1573-9. PubMed ID: 20304628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S
    J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis.
    Kogure Y; Yoshimi A; Ueda K; Nannya Y; Ichikawa M; Nakamura F; Kurokawa M
    Ann Hematol; 2015 Jun; 94(6):989-94. PubMed ID: 25687839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
    Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
    Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab.
    Aguiar Bujanda D
    Ann Oncol; 2008 Feb; 19(2):396-7. PubMed ID: 18245132
    [No Abstract]   [Full Text] [Related]  

  • 39. Histone deacetylase inhibitor abexinostat (S78454/PCI-24781) as a successful approach in a case of refractory peripheral angio-immunoblastic T-cell lymphoma, as a bridge to reduced intensity conditioning haplo-identical allogenic stem cell transplant.
    Saillard C; El Cheikh J; Granata A; Coso D; Schiano JM; Bouabdallah R; Blaise D; Charrier N; Broussais F
    Leuk Lymphoma; 2016; 57(3):714-6. PubMed ID: 26750740
    [No Abstract]   [Full Text] [Related]  

  • 40. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
    Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
    J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.